In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
ICON Oncology’s Opinion of How We Can Reach for the Stars With a Moonshot
Dr. Martin Lachs, Dr. Reinhard Eisebitt and Dr. Valerii Fedorov contribute to this article inClinical Oncologist Dailyon ICON's decision to invest in aCancer Moonshot project using quantum computing.
-
APAC is the fastest growing market for CRO industry
In this article, Mary Pan outlines the growth and trends ofclinical trials in the APAC region.
-
Effective Sponsor-CRO Collaboration
In this PharmaVOICE article, read commentary from Dr. Phil Birch on effectivesponsor-CRO collaboration.
-
ICON Recognised for Excellence in Vaccine Development
Coverage of ICON's recent award at the ViE Awards. these awards honor individuals and organisations that continually set standards of excellence and have made outstanding achievements in the vaccine industry.
-
Predatory Journals Are Back in the Firing Line
Learn how to spot apredatory journalwith these tips from PubsHub.
-
Overcoming Four Challenges to Successful Rare Disease Drug Development
ICON contributed to this article in Pharmafocus relating to overcoming four challenges to greatly improve the chances for a successful rare or “orphan” drug trial.
-
Why a Patient's Experience with a Drug Matters
Patient reported outcomesare often the primary endpoints in FDA approved pain drugs. Andy Smith shares his insights inMednous.
-
PRO Instruments to Improve Endpoints for Antibacterial Drug Trials
Brittany Erana contributes to this article that features theFDA's selection ofICON to validate PRO instruments used to access clinical endpoints in antibacterial drug trials.
-
Cell and Gene Therapies: On Course for Commercial Success?
Rebecca Walker contributes to this PMLiVE article oncell and gene therapies.
-
Market Access 2017: A European Perspective
Ramita Tandon was interviewed in “Market Access 2017: A European Perspective” in the Pharmaceutical Executive. The article discusses how UK and European regulators’ market access plans for 2017 will affect the industry.
